•
Mar 31, 2022
Edgewise Therapeutics Q1 2022 Earnings Report
Reported financial results for the first quarter of 2022.
Key Takeaways
Edgewise Therapeutics reported a net loss of $14.7 million, or $0.30 per share, for the first quarter of 2022. Cash, cash equivalents, and marketable securities totaled $265.8 million as of March 31, 2022. The company anticipates its cash resources will be sufficient to support planned growth and operations through 2024.
Completed enrollment of the ARCH open label study of EDG-5506 in Becker muscular dystrophy (BMD).
Initiated enrollment in Edgewise-funded Natural History Trial of BMD.
Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) are planned to start in 2022.
Cash, cash equivalents and marketable securities of $265.8 million as of March 31, 2022.